Polymyositis News

Conventional memory B cells with low CXCR5 levels and CXCR5 T-helper 2 memory cells are potential biomarkers of juvenile dermatomyositis disease activity, according to data published in Arthritis & Rheumatology.

PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Rituximab is comparable in terms of safety and efficacy to cyclophosphamide among patients with interstitial lung disease associated with connective tissue diseases, according to data presented at ACR Convergence 2022.

PHILADELPHIA — High risk factors for cancer in patients with idiopathic inflammatory myopathy include dermatomyositis, anti-TIF1-gamma positivity, anti-NXP2 positivity and age 40 or older at onset, said a speaker here.

Apremilast may be an efficacious and safe treatment option for patients with recalcitrant cutaneous dermatomyositis, according to a study.

Earlier this year, a group of researchers published data from long-term extension study of tofacitinib in patients with dermatomyositis, demonstrating a “sustained response” to a pan-JAK inhibitor in this population.

For all the multitudes of diseases and diversity of organ systems rheumatologists are adept at managing and analyzing, the brain, spinal cord and related neurological conditions are often not among them.

SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for inclusion body myositis, according to a speaker at the Congress of Clinical Rheumatology West.

The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.